HIV
and Hepatitis.com Coverage of the 14th
Annual Conference on Retroviruses and Opportunistic Infections (14th CROI) February
25 - 28, 2007, Los Angeles, CA
Tenofovir
Regimens Show Greater Virologic Suppression in Treatment-naïve Blacks Compared
to Thymidine Analog Regimens
Prior
studies have demonstrated that responses to therapy and adverse side effects may
vary significantly in HIV patients of different races. Researchers at medical
centers in the US, UK and Germany assessed the outcomes of two Phase III antiretroviral
drug trials that had enrolled 20-25% black
patients (n=228).
The analysis of the results of the two Phase III trials
demonstrated significantly greater virologic suppression from the TDF-containing
regimen than from thymidine analog-based (stavudine- or zidovudine-based) therapy
in black, treatment-naïve patients through 96 weeks.
In addition,
the researchers found that the patients in the TDF-based arm had significantly
lower increases in total cholesterol
and triglycerides. There was no significant difference in renal function between
the two study arms.
Johns Hopkins Univ Sch of Med, Baltimore, MD, US;
Chelsea and Westminster Hosp, London, UK; JW Goethe Univ, Frankfurt, Germany;
Orlando Immunology Ctr, FL, US; and Gilead Sci, Foster City, CA, US. Link
to full study abstract.
Johns Hopkins Univ Sch of Med, Baltimore, MD,
US; Chelsea and Westminster Hosp, London, UK; JW Goethe Univ, Frankfurt, Germany;
Orlando Immunology Ctr, FL, US; and Gilead Sci, Foster City, CA, US.
03-02-07 Reference
J Gallant, A Pozniak, S Staszewski, and others. Efficacy and Safety of Tenofovir-containing
vs non-Tenofovir-containing Regimens in Black ART-naive Patients. 14th CROI. February
25-28, 2007. Los Angeles, CA. Abstract 505.
